BioNTech SE (BNTX) Capital Expenditures (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Capital Expenditures data on file, last reported at -$73.6 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 3.37% year-over-year to -$73.6 million; the trailing twelve-month figure through Dec 2025 stood at -$197.6 million (up 36.26% YoY), and the FY2025 full-year result was -$197.8 million, up 35.38% from the prior year.
• Capital Expenditures declined to -$73.6 million in Q4 2025, from -$42.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$26.18 in Q1 2021 to a low of -$139.4 million in Q4 2022.
• A 5-year average of -$65.0 million and a median of -$67.4 million in 2024 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures soared 100.0% in 2021 and sank 189090564.66% in 2022, its largest moves.
• Tracing BNTX's Capital Expenditures over 5 years: stood at -$45.1 million in 2021, then sank by 209.2% to -$139.4 million in 2022, then jumped by 35.3% to -$90.2 million in 2023, then advanced by 21.07% to -$71.2 million in 2024, then retreated by 3.37% to -$73.6 million in 2025.
• Business Quant data shows BNTX's Capital Expenditures at -$73.6 million in Q4 2025, -$42.0 million in Q3 2025, and -$30.7 million in Q2 2025.